Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -354.93% is in line with its 5-year average of -330.86%, near the high end of its 5-year range (-2039.47%–28.00%).
25.53% above its 12-month average of -476.59%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): -269.70%.
GROSS MARGIN
-354.93%
GROSS MARGIN AVG TTM
-476.59%
GROSS MARGIN AVG 3Y
-381.28%
GROSS MARGIN AVG 5Y
-330.86%
GROSS MARGIN AVG 10Y
-32.57%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+25.53%
CURRENT VS 3Y AVG
+6.91%
CURRENT VS 5Y AVG
-7.27%
CURRENT VS 10Y AVG
-989.61%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-957.73%
vs the sector median at left
PAVmed Inc.
Market Cap
$17.07M
Gross Margin
-354.93%
TTM Avg
-476.59%
3Y Avg
-381.28%
5Y Avg
-330.86%
Market Cap
$16.84M
Gross Margin
0.00%
TTM Avg
-52.16%
3Y Avg
-139.89%
5Y Avg
-776.52%
Market Cap
$17.31M
Gross Margin
-334.26%
TTM Avg
-117.13%
3Y Avg
-347.18%
5Y Avg
-222.70%
Market Cap
$16.82M
Gross Margin
72.24%
TTM Avg
86.12%
3Y Avg
93.06%
5Y Avg
-220.71%
Market Cap
$17.39M
Gross Margin
10.27%
TTM Avg
10.01%
3Y Avg
10.00%
5Y Avg
11.56%
Market Cap
$16.74M
Gross Margin
99.63%
TTM Avg
49.76%
3Y Avg
72.18%
5Y Avg
92.05%
Market Cap
$16.64M
Gross Margin
21.95%
TTM Avg
11.59%
3Y Avg
17.76%
5Y Avg
20.87%
Market Cap
$16.52M
Gross Margin
-88.25%
TTM Avg
-11.22%
3Y Avg
9.24%
5Y Avg
11.19%
Market Cap
$18.30M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PAVmed Inc. (PAVM) | $17.07M | -354.93% | -476.59% | -381.28% | -330.86% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | 0.00% | -52.16% | -139.89% | -776.52% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -334.26% | -117.13% | -347.18% | -222.70% |
| TScan Therapeutics, Inc. (TCRX)vs › | $16.82M | 72.24% | 86.12% | 93.06% | -220.71% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | 10.27% | 10.01% | 10.00% | 11.56% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | 99.63% | 49.76% | 72.18% | 92.05% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | 21.95% | 11.59% | 17.76% | 20.87% |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | -88.25% | -11.22% | 9.24% | 11.19% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.30M | 0.00% | 0.00% | 0.00% | 0.00% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | 0.00% | -3731.89% | -2384.22% | -1567.12% |
Gross Margin
-354.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | -269.70% |
| 2026-03-31 | -431.82% |
| 2025-12-31 | -98.08% |
| 2025-09-30 | -1000.00% |
| 2025-06-30 | -583.33% |
| 2025-03-31 | -887.50% |
| 2024-12-31 | -380.00% |
| 2024-09-30 | -38.65% |
| 2024-06-30 | -101.33% |
| 2024-03-31 | -72.67% |
| 2023-12-31 | -53.57% |
| 2023-09-30 | -124.91% |
| 2023-06-30 | -915.06% |
| 2023-03-31 | -201.79% |
| 2022-12-31 | -1344.64% |
| 2022-09-30 | -2039.47% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | -95.24% |
| 2021-12-31 | -47.00% |
| 2021-09-30 | 28.00% |
| 2021-06-30 | 0.00% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
| 2017-12-31 | 0.00% |
| 2017-09-30 | 0.00% |
| 2017-06-30 | 0.00% |
| 2017-03-31 | 0.00% |
| 2016-12-31 | 0.00% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 0.00% |
| 2015-06-30 | 0.00% |
| 2015-03-31 | 0.00% |
